Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. CanSino Biologics Inc.
  6. News
  7. Summary
    6185   CNE100003F01

CANSINO BIOLOGICS INC.

(6185)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

CanSino Biologics Inc. Announces Earning Guidance for the Six Months Ended June 30, 2021

07/16/2021 | 07:07am EDT

The board of directors of CanSino Biologics Inc. announced that the shareholder and potential investors of the Company that, based on the information currently available to the Group and its preliminary assessment of the unaudited consolidated management accounts of the Group for the six months ended June 30, 2021, it is expected that the Group's net profit will turn around during the Reporting Period as compared to the corresponding period in 2020. The Group is expected to record a net profit attributable to owners of the Company of approximately RMB 900.0 million to RMB 1,050.0 million during the Reporting Period (corresponding period in 2020: net loss attributable to owners of the Company of approximately RMB 102.2 million). The net profit attributable to owners of the Company after deducting the non-recurring profit or loss during the Reporting Period is expected to be approximately RMB850.0 million to RMB1,000.0 million (corresponding period in 2020: net loss attributable to owners of the Company after deducting the non-recurring profit or loss of approximately RMB 116.3 million). In addition, the Group is expected to record a revenue of approximately RMB 2,000.0 million to RMB 2,200.0 million for the Reporting Period (corresponding period in 2020 under Hong Kong Financial Reporting Standards: nil).


© S&P Capital IQ 2021
All news about CANSINO BIOLOGICS INC.
09/10Cansino Biologics Inc. Announces Executive Changes
CI
09/07CANSINO BIOLOGICS : Indonesia approves J&J, Cansino COVID-19 vaccines for emerge..
RE
09/07SINOVAC BIOTECH : Mixing CanSinoBIO, Sinovac COVID shots induces stronger respon..
RE
09/06CORONAVIRUS PANDEMIC : Chinese developer shares efficacy of inhaled vaccines
PU
08/27CANSINO BIOLOGICS : COVID shot drives CanSinoBIO's first six-month profit since ..
RE
08/27Cansino Biologics Inc. Reports Audited Consolidated Earnings Results for the ..
CI
08/13CANSINO BIOLOGICS INC.(SHSE : 688185) added to Shanghai Stock Exchange A Share I..
CI
08/13CANSINO BIOLOGICS INC.(SHSE : 688185) added to Shanghai Stock Exchange Composite..
CI
08/13Certain A Shares of CanSino Biologics Inc. are subject to a Lock-Up Agreement..
CI
08/06CANSINO BIOLOGICS : CanSinoBIO COVID-19 says booster shot can reverse drop in an..
RE
More news
Analyst Recommendations on CANSINO BIOLOGICS INC.
More recommendations
Financials
Sales 2021 9 984 M 1 544 M 1 544 M
Net income 2021 5 282 M 817 M 817 M
Net cash 2021 5 073 M 785 M 785 M
P/E ratio 2021 11,6x
Yield 2021 0,00%
Capitalization 40 396 M 6 248 M 6 248 M
EV / Sales 2021 3,54x
EV / Sales 2022 0,98x
Nbr of Employees 726
Free-Float 37,1%
Chart CANSINO BIOLOGICS INC.
Duration : Period :
CanSino Biologics Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CANSINO BIOLOGICS INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Last Close Price 232,64 CNY
Average target price 308,77 CNY
Spread / Average Target 32,7%
EPS Revisions
Managers and Directors
Xue Feng Yu Chairman, Chief Executive Officer & GM
Xi Luo Chief Financial Officer
Jiang Feng Li Chairman-Supervisory Board
Tao Zhu Executive Director, CSO & Deputy General Manager
Jun Qiang Li Senior Director-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
CANSINO BIOLOGICS INC.58.64%11 022
CSL LIMITED9.25%102 521
WUXI BIOLOGICS (CAYMAN) INC.19.75%67 077
SAMSUNG BIOLOGICS CO.,LTD.12.95%52 329
BIOGEN INC.22.60%44 738
ALEXION PHARMACEUTICALS, INC.0.00%40 336